(Albany, US) Delveinsight has launched a new report on Complement 3 Glomerulopathy Epidemiology
DelveInsight’s Complement 3 Glomerulopathy Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Complement 3 Glomerulopathy (C3G) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Complement 3 glomerulopathy (C3G) was adopted by expert consensus in 2013 to define a group of rare kidneys diseases driven by dysregulation of the complement cascade. It is a type of glomerular disease, characterized by predominant C3 complement component (C3) deposits in the glomeruli in the absence of a significant amount of immunoglobulin and without deposition of C1q and C4. The term C3G includes dense deposit disease (DDD) and C3 glomerulonephritis (C3GN), which are the two patterns of damage and inflammation in the glomeruli. In other words, the damage and inflammation in the kidney tissue in DDD appear different from that in C3GN when observed under a microscope. People with DDD generally present at a younger age (childhood or adolescence) compared to people with C3GN (adulthood). In DDD, C3 deposits are bunched up in one area of the glomeruli and appear thick while in case of C3GN, C3 deposits are more spread out and less thick. Progression to end-stage renal disease (ESRD) has been found in 40% of C3G patients, with no detectable difference between those with C3GN versus DDD. Dysregulation of the complement alternative pathway, driven by acquired and/or genetic defects, plays a pathogenetic role in C3G. However, alternative pathway abnormalities are also found in IC-MPGN (immune-complex-MPGN). The most common acquired drivers of C3G are the C3 nephritic factors (C3NeFs),heterogeneous autoantibodies that stabilize the C3 convertase, C3bBb.
Request for free sample page:- https://www.delveinsight.com/sample-request/complement-3-glomerulopathy-c3g-epidemiology-forecast
Complement 3 Glomerulopathy Epidemiology Perspective
The Complement 3 Glomerulopathy (C3G) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Complement 3 Glomerulopathy (C3G) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Complement 3 Glomerulopathy (C3G) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders..
Complement 3 Glomerulopathy Epidemiology
As per the National Organization for Rare Disorders (NORD), C3G affects persons of all ages, although the mean age appears to be lower in DDD patients as compared to C3GN patients. The prevalence of C3G is estimated at 2–3 per 1,000,000 people. The dynamics of C3G market is anticipated to change in the coming years owing to the improvement in the research and development activities so that market will comprise of efficient treatment options. The launch of emerging therapies is expected during the forecast period of 2020-2030.
Key facts of the report
Scope of the Report
Table of content
1. Key Insights
2. Executive Summary of Complement 3 Glomerulopathy (C3G)
3. Complement 3 Glomerulopathy (C3G): Disease Background and Overview
4. Patient Journey
5. Epidemiology and Patient Population
6. Treatment Algorithm, Current Treatment, and Medical Practices
7. KOL Views
8. Unmet Needs
9. Appendix
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
Why should you buy this report?
Related Reports
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/